• Publications
  • Influence
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
TLDR
Digoxin administration increased latency and decreased growth of tumor xenografts, whereas treatment of established tumors resulted in growth arrest within one week, demonstrating that HIF-1 is a critical target of digoxin for cancer therapy. Expand
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.
TLDR
Treatment of the VHL-deficient human renal cell carcinoma cell line UMRC2 with the hydroxamic HDAC inhibitor LAQ824 resulted in a dose-dependent inhibition of HIF-1 alpha protein via a V HL-independent mechanism and reduction of Hif-1alpha transcriptional activity, suggesting that class II HDACs are associated with HIF's alpha stability. Expand
Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells
TLDR
A cell-based reporter gene assay provides a molecular basis for the antiangiogenic effect of anthracycline therapy and has important implications for refining the use of these drugs to treat human cancer more effectively. Expand
Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
TLDR
Results provide proof of principle that small molecules can inhibit dimerization of HIF-1 and have potent inhibitory effects on tumor growth and vascularization. Expand
HDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia*
TLDR
The novel biological relationship between HDAC4 and HIF1α presented here suggests a potential role for the deacetylase enzyme in regulating HIF-1 cancer cell response to hypoxia and presents a more specific molecular target of inhibition. Expand
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.
TLDR
It is shown that in addition to blocking cell division, docetaxel impairs AR signaling, evidence that enables new insights into the therapeutic efficacy of microtubule-targeting drugs in prostate cancer. Expand
The N-Myc Down Regulated Gene1 (NDRG1) Is a Rab4a Effector Involved in Vesicular Recycling of E-Cadherin
TLDR
It is reported that NDRG1 is involved in recycling the adhesion molecule E-cadherin thereby stabilizing it and will aid in understanding N DRG1 role as a metastasis suppressor protein. Expand
Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589
TLDR
Evidence is provided that LBH589 induces a wide range of effects on endothelial cells that lead to inhibition of tumor angiogenesis, which support the role of HDAC inhibitors as a therapeutic strategy to target both the tumor and endothelial compartment and warrant the clinical development of these agents in combination with angiogenic inhibitors. Expand
The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor
TLDR
The results suggest that the combination of histone deacetylase inhibitors and VEGF receptor inhibitors may target multiple pathways in tumor progression and angiogenesis and represents a novel therapeutic approach in cancer treatment. Expand
Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias
TLDR
The clearance of marrow blasts in some patients after bevacizumab suggests that VEGF neutralization might result directly in leukemic cell death, and the potential biological and clinical activity of bevazquezumab in AML warrants additional clinical and laboratory study. Expand
...
1
2
3
4
5
...